such by the Royal Society for Public Health, the Royal College of Physicians, and Public Health England in the UK. [8] [9] [10] However, many other organisations including the World Health Organization (WHO), American Lung Association and Australian Medical Association do not support the use of ENDS as a cessation aid in youth, citing concerns regarding product safety and the potential that experimentation with ENDS could lead to nicotine dependence and subsequent tobacco use. [11] [12] [13] Evidence supporting such concerns was also documented in the recent US Surgeon General Report.
14 As experimentation with cigarettes primarily occurs in youth (ages 10-24 years), 15, 16 and the developing brain is particularly sensitive to nicotine, 17 the use of ENDS during youth has received considerable attention. 8, 18 In many jurisdictions, ENDS products are actively marketed in ways that appeal to young people, including the use of celebrity product endorsements and promotion of flavoured products (e.g. 'candy' flavour), and via social media. 19 Although many jurisdictions where ENDS can be legally purchased have bans on sales to minors when the e-liquid contains nicotine, [20] [21] [22] ENDS are often easily obtained through informal social sources, such as friends and family members. 23 Further, few countries enforce age restrictions on the purchase of e-liquids that do not contain nicotine. 22 Recent metaanalyses of youth cohort studies published by the WHO 24 and others 69 suggest that use of ENDS by non-smoking young people can as much as quadruple the odds of later tobacco use. 25 Given the availability and promotion of ENDS in many countries, and their potential to influence tobacco use in youth, an understanding of the prevalence of ENDS use in young people generally, and among smokers and non-smokers, is needed to assess their potential impact on population health.
To our knowledge, just three systematic reviews have described the prevalence of ENDS use in young people, [26] [27] [28] none of which synthesised findings via meta-analysis, or considered the non-English literature, [26] [27] [28] thus limiting their ability to provide global estimates of the prevalence of ENDS use in youth. Given the documented increase in ENDS use among young people in recent years, 29-31 a comprehensive review and meta-analyses of the prevalence of ENDS use is needed. In view of the differences across countries in the timing of the introduction of ENDS, and of the implementation of regulations regarding their availability, purchase, and use, 32, 33 it is crucial to examine the differences in the prevalence of ENDS use across countries, and to examine changes in prevalence within countries over time. Such data are required to better inform future tobacco control efforts, and public health policy as evidence regarding the potential benefits and harms of ENDS use continues to advance.
Objectives
The aims of this review are to: 1) describe the prevalence of ENDS use ('ever' and 'current') in young people aged ≤20 years by country and combustible tobacco smoking status (non-smokers and current smokers) during the 2013-2015 period; and 2) describe the changes in ENDS use (ever and current) in youth over time (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) by country.
Methods
The study reports data from a review undertaken on behalf of the WHO. A full description of the review methods is provided elsewhere.
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Search strategy and study eligibility Broadly, the search terms included e-cig*, electronic nicotine*, electronic hookah* and e-hookah* as MESH terms (see Appendix A of the online supplementary file). A screen of the first 750 hits of a 'Google.com' search including the terms 'electronic cigarette' and 'e-cigarette' was also undertaken by one reviewer (FT) to capture the grey literature.
Information on potentially eligible studies was also sought from 30 experts recommended by the Tobacco Unit of the WHO, and from selected authors who had published two or more relevant studies in the field.
All studies identified in the searches were exported into EndNote X6 for screening by two reviewers (SY, LW). 'Google translate' was used to assist with assessing the eligibility of non-English language manuscripts.
Data extraction and study quality assessment
SLY and LW or LKC extracted the study characteristics, and prevalence of ENDS use by smoking statuses using a standardised form. Where prevalence of ENDS use by current smokers and non-smokers were not reported, estimates of use were calculated using the following information provided in the original publications: number in total sample, prevalence of ENDS users, prevalence of smokers, and prevalence of concurrent ENDS and tobacco users. A consensus process was used to resolve any differences in extraction. For the included studies, other supporting publications or reports were also sought to obtain relevant information where the data from the primary study was absent or unclear.
Two reviewers (MK and FT) independently undertook an assessment of study quality using the Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence Data. [34] [35] Any discrepancies were resolved via discussion with a third reviewer (SY).
Data synthesis and analyses
All analyses were undertaken using Stata version 14 software 36 and the METAPROP package. 'Ever' users were defined as those who had ever used ENDS in their lifetime (including studies that described participants as 'occasional' users), and 'current' use was defined as use in past 30 days, or where studies described participants as being 'current' or 'regular' users. Non-smokers were defined as those not currently smoking (including ex-smokers and never smokers) and smokers were defined as those currently smoking (including experimental, occasional or current users).
For Aim 1, where multiple studies provided estimates of ENDS prevalence between 2013 and 2015 for a single country, data were pooled using a random effects meta-analysis, weighted according to the inverse variance method. The Freeman-Tukey double arcsine transformation of prevalence was also used to allow for studies with prevalence that was close to zero and to account for data skewness. Exact 95% confidence intervals for the individual studies were computed, and stratified by country (where available). Pooled estimates of prevalence are reported as an absolute percent with 95% confidence intervals. For Aim 2, data were pooled where multiple studies reported prevalence estimates for the same country for the same year, and produced estimates for each year of data available. Heterogeneity was assessed using the I-squared statistic and reported for each point estimate, together with estimates of the between study variance, and corresponding p-values.
Results

Study characteristics and study quality assessment
Overall, 27 studies that reported findings from 36 individual surveys were included (see Figure S1 , online supplementary Appendix for PRISMA flowchart). The included studies were conducted in 13 countries: the US (national and subnational) (n=10); [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] reported that the majority (72%) of ENDS ever users used ENDS without nicotine. However, these results were only presented for regular users 58 or ever users 53 in the studies, respectively. All study characteristics are reported in Table S1 (online supplementary file). When evaluated using the Joanna Briggs Institute Critical Appraisal Checklist, most studies used samples that were representative of the target population (n=18); conducted appropriate participant recruitment (n=26); and had an adequate sample size (n=23). Most (n=19) described the subjects and setting in detail; however, eight did not. The objectivity and reliability of the measures of ENDS use were mostly unclear, as data were collected via self-report. Important confounders or subgroup differences were accounted for in 18 studies. All 27 studies conducted appropriate statistical analyses (see Figures S2 and S3 in online supplementary Appendix C).
Current prevalence of ENDS use among adolescents
Prevalence of ENDS use among all youth
Estimates of the prevalence of ENDS use from studies conducted in nine countries between 2013 and 2015 are presented in Figures 1  and 2 . Rates of ever use among youth were highest in Poland (one data point, 62.1%; 95%CI: 59.9-64.2%), and lowest in Italy (three data points, 5.9%; 95%CI: 3.3-9.2%). Rates of current use among youth were highest in Poland (one data point, 29.9%, 95%CI: 27.9-32.0%) and lowest in New Zealand (one data point, 0.0%; 95%CI: 0.0-3.7%), see Figure 2 .
Prevalence of ENDS use among nonsmoking youth
Estimates Figure S7 ). Figure 1 : Prevalence of ENDS ever use among youth, by country for all respondents (smokers and non-smokers).
Change in ENDS use among youth over time
Figure 1: Prevalence of ENDS ever use among youth, by country for all respondents (smokers and non-smokers).
© 2018 The Authors drawn from studies with repeated samples of the same participants over time; however, estimates for Korea, Canada and the UK comprised different samples over time (see supplementary Table S2 ). Table S3 ), and both estimates were drawn from studies with repeated samples of the same participants over time.
Discussion
The findings are consistent with previous reviews that found that current smokers were more likely to use ENDS, 61 and that ENDS ever and current use was increasing in the majority of countries with multiple prevalence estimates. 25 While considerable heterogeneity in prevalence estimates were reported across countries, ENDS use appeared to be increasing in most countries among young people. Such findings provide useful information for policy makers who are responsible for implementing tobacco control initiatives.
In interpreting these study results, it is important to consider that data were only available in 13 countries, with 10 of 27 included studies from the US. 39, 48, 64 Third, the majority of included studies (93%) did not record whether the ENDS use included nicotine and/or nonnicotine e-liquids. This is an important distinction to consider in future studies of ENDS use in young people, given that concerns have been raised regarding the susceptibility of the adolescent brain to early exposure to nicotine, and the possibility that ENDS experimentation could lead to nicotine dependence in adulthood. Finally, although several studies conducted repeated measures of ENDS use on the same population using the same survey methods, other studies did not and, as such, the country-level changes in ENDS prevalence should be interpreted with caution and validated with longitudinal cohort studies when they become available.
While prevalence of current ENDS use was typically low among non-smokers, increasing use among this group may be a concern in light of recent longitudinal studies reporting a positive association between ENDS ever use and subsequent uptake of cigarette smoking at 12-month follow-up. 21, [66] [67] [68] [69] Future studies should continue to monitor prevalence of ENDS ever and current use among youth, particularly among non-smokers, to enable pooling and comparisons between countries. Given the marked differences observed between countries in the prevalence of ENDS Figure 2 : Prevalence of ENDS current use among youth, by country for all respondents (smokers and non-smokers) 
